Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kaneko, T; Hirji, S; Zaid, S; Lange, R; Kempfert, J; Conradi, L; Hagl, C; Borger, AM; Taramasso, M; Nguyen, CT; Ailawadi, G; Shah, SA; Smith, LR; Anselmi, A; Romano, AM; Ben Ali, W; Ramlawi, B; Grubb, JK; Robinson, BN; Pirelli, L; Chu, WAM; Andrea, M; Obadia, JF; Gennari, M; Garatti, A; Tchetche, D; Nazif, MT; Bapat, NV; Modine, T; Denti, P; Tang, HLG.
Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair Mid-Term Outcomes From the CUTTING-EDGE International Registry
JACC-CARDIOVASC INTE. 2021; 14(18): 2010-2021.
Doi: 10.1016/j.jcin.2021.07.029
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Andreas Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER). BACKGROUND Although >100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking. METHODS Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year. RESULTS From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 +/- 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median in-terval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery. CONCLUSIONS In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only <10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes. (J Am Coll Cardiol Intv 2021;14:2010-2021) (c) 2021 by the American College of Cardiology Foundation.
- Find related publications in this database (Keywords)
- mitral valve replacement
- mitral valve surgery
- transcatheter edge-to-edge repair